Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Rhinomed Limited
  6. News
  7. Summary
    RNO   AU000000RNO1

RHINOMED LIMITED

(RNO)
End-of-day quote. End-of-day quote Australian Stock Exchange - 12/06
0.29 AUD   0.00%
11/18RHINOMED : CEO presentation to 2021 AGM
PU
11/10Investor update November 2021
PU
10/26Rhinomed Secures Ethics Approval for Post-Market Trial of Nasal Swab Product
MT
SummaryChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Rhinomed Limited Receives an Initial Purchase Order for One Million Rhinoswabs from the Victorian Department of Health to Support Victoria's Testing Capability

09/09/2021 | 07:23pm EST

Rhinomed Limited has received an initial purchase order for one million Rhinoswabs from the Victorian Department of Health (DH) to support Victoria's testing capability. This follows the recent NSW Health Pathology order of one million Rhinoswabs as announced on 11 August. Rhinomed's Rhinoswab technology improves the sample collection process. As previously disclosed the Rhinoswab is substantially more comfortable and easier to use than the standard nasal swab, captures a larger sample, can accelerate the sample collection process and significantly reduce queues and waiting times. Rhinoswab works with existing PCR pathology workflows and equipment and has equivalent cost and quality to the US and European standard of care nasopharyngeal swabs. Rhinomed is continuing to scale up its manufacturing capabilities to accommodate growing domestic and international demand for this innovative technology. The Rhinoswab is registered with the US FDA, Australian TGA and has a European CE mark. The company is developing an increasing sales pipeline and will update investors as further agreements occur. The revenue associated with this order represents approximately 35%-45% of unaudited FY21 revenues of $3.9m. The details of the order are commercial in confidence. This announcement discloses all material details as required under section 4.15 of Guidance Note 8.


ę S&P Capital IQ 2021
All news about RHINOMED LIMITED
11/18RHINOMED : CEO presentation to 2021 AGM
PU
11/10Investor update November 2021
PU
10/26Rhinomed Secures Ethics Approval for Post-Market Trial of Nasal Swab Product
MT
10/26Rhinoswab Clinical Trial Approves At St Vincent's Hospital
CI
10/19RHINOMED : New swab takes away children's fear of swabbing
EQ
09/28Rhinomed Limited Auditor Raises 'Going Concern' Doubt
CI
09/13Rhinomed Limited Appoints Rhinoswab Distributors for Australia and Belgium, the Netherl..
CI
09/10RHINOMED : to Deliver One Million COVID-19 Nasal Swabs to Australia's Victoria Government
MT
09/09Rhinomed Limited Receives an Initial Purchase Order for One Million Rhinoswabs from the..
CI
08/26Rhinomed Limited Announces Ethics Approval Granted for Clinical Trial of First Nasal Sw..
CI
More news
Financials
Sales 2021 4,42 M 3,12 M 3,12 M
Net income 2021 -8,64 M -6,09 M -6,09 M
Net cash 2021 1,87 M 1,32 M 1,32 M
P/E ratio 2021 -4,55x
Yield 2021 -
Capitalization 73,6 M 51,9 M 51,9 M
EV / Sales 2020 2,37x
EV / Sales 2021 8,48x
Nbr of Employees -
Free-Float 31,3%
Chart RHINOMED LIMITED
Duration : Period :
Rhinomed Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RHINOMED LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
Michael Johnson Chief Executive Officer, MD & Executive Director
Sean Slattery Chief Financial Officer & Secretary
Ronald R. Dewhurst Non-Executive Chairman
Brent J. Scrimshaw Independent Non-Executive Director
Eric Knight Independent Non-Executive Director
Sector and Competitors